• Bolaños J. P. and Heales S. J. (2010) Persistent mitochondrial damage by nitric oxide and its derivatives: neuropathological implications. Front Neuroenergetics 2, 1.
  • De Simoni S., Goemaere J. and Knoops B. (2008) Silencing of peroxiredoxin 3 and peroxiredoxin 5 reveals the role of mitochondrial peroxiredoxins in the protection of human neuroblastoma SH-SY5Y cells toward MPP+. Neurosci. Lett. 433, 219224.
  • De Simoni S., Linard D., Hermans E., Knoops B. and Goemaere J. (2013) Mitochondrial peroxiredoxin-5 as potential modulator of mitochondria-ER crosstalk in MPP+-induced cell death. J. Neurochem. doi:10.1111/jnc.12117.
  • Lee D. H., Han Y. S., Han E. S., Bang H. and Lee C. S. (2006) Differential involvement of intracellular Ca2+ in 1-methyl-4-phenylpyridinium- or 6-hydroxydopamine-induced cell viability loss in PC12 cells. Neurochem. Res. 31, 851860.
  • Qu D., Rashidian J., Mount M. P. et al. (2007) Role of Cdk5-mediated phosphorylation of Prx2 in MPTP toxicity and Parkinson's disease. Neuron 55, 3752.
  • Schapira A. H., Cooper J. M., Dexter D., Jenner P., Clark J. B. and Marsden C. D. (1989) Mitochondrial complex I deficiency in Parkinson's disease. Lancet 1, 1269.
  • Telford J. E., Kilbride S. M. and Davey G. P. (2009) Complex I is rate-limiting for oxygen consumption in the nerve terminal. J. Biol. Chem. 284, 91099114.